Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 94980 results found since Jan 2013.
The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy
ConclusionSCIT was more frequently provided than SLIT by all the specialties. Otolaryngologists were the most likely to offer SLIT, while very few allergist/immunologists offered SLIT. Allergist/immunologists differed from other specialties in some beliefs about the effectiveness of AIT.
Source: International Forum of Allergy and Rhinology - August 14, 2014 Category: Allergy & Immunology Authors: Bryan Leatherman, David P. Skoner, James A. Hadley, Nicole Walstein, Michael S. Blaiss, Mark S. Dykewicz, Timothy Craig, Nancy Smith, Felicia Allen‐Ramey Tags: ORIGINAL ARTICLE Source Type: research
Top 10 Mesothelioma and Asbestos News Stories of 2020
Growing allegations of asbestos-contaminated talc in various consumer products, coupled with historic approval of a new treatment for pleural mesothelioma, made 2020 a year filled with both anxiety and hope.
Johnson & Johnson stopped selling its iconic baby powder in May after being hit by thousands of lawsuits contending its talc-based product was causing various cancers, including ovarian cancer and malignant mesothelioma.
The U.S. Food and Drug Administration approved the immunotherapy combination of Opdivo and Yervoy in October, the first new drug regimen approved for first-line treatment of unresectable disease in...
Source: Asbestos and Mesothelioma News - December 15, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
Teaching Teens to Get Serious About Sun Safety
What’s Up with Tiffany’s Dad?Medikidz Explain Melanoma By Kim Chilman-Blair and Shawn deLoacheA summer sunburn or a trip to the tanning bed may seem like no big deal to the average teenager. However, overexposing your skin to the harmful UV rays found in sunlight and tanning lights as a teenager can add up to an increased risk of skin cancer as an adult. This year, it is estimated that more than 75,000 people in the U.S. will be diagnosed with melanoma, the deadliest form of skin cancer, and in spite of the serious effects of this disease, many teens will not take the steps they need to protect their skin and r...
Source: American Cancer Society :: News and Features - July 7, 2016 Category: Cancer & Oncology Tags: Skin Cancer - Melanoma Sun Safety/Tanning Source Type: news
FDA Approves Gene Therapy Tested In Boston To Treat Adults With Lymphoma
TRENTON, N.J. (CBS/AP) — U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.
The Food and Drug Administration allowed sales of the treatment from Kite Pharma. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals.
That Novartis treatment was tested in Boston. In those tests, Dana Farber and Brigham and Women’s Hospital cancer researchers found that 80 percent of lymphoma patients who underwent the treatment we...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 19, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Healthwatch Local News blood cancer Brigham and Women's Hospital Dana Farber FDA Gene Therapy Novartis Pharmaceuticals Source Type: news
Top 10 Mesothelioma News Stories of 2017
Every year, mesothelioma specialists and researchers make strides to advance the standard of care, improve treatment strategies and develop new diagnostic practices.
Mesothelioma remains a rare cancer, with an estimated 3,000 people diagnosed each year in the U.S., but the fight to find a cure only grows stronger.
And while researchers are busy finding breakthroughs in care, advocates are hard at work campaigning for a ban on asbestos, the main cause of mesothelioma.
This was a memorable year on both fronts.
Immunotherapy continues to be the hot topic among emerging treatments. Drugs such as pembrolizumab (Keytruda) and ni...
Source: Asbestos and Mesothelioma News - December 22, 2017 Category: Environmental Health Authors: Daniel King Tags: canada asbestos ban Food and Drug Administration Furthering Asbestos Claims Transparency Act keytruda Medical marijuana mesothelioma mesothelioma vaccine Opdivo Scott Pruitt talcum powder lawsuit yervoy Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu érin-Unresponsive Non-Muscle-Invasive Bladder Cancer
CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administered intravenously) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for, or decline, radical cystectomy. The study demonstrated that 72.7 percent of patients treated wit...
Source: Johnson and Johnson - April 30, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
Abstract
CD1d-restricted invariant natural killer T (iNKT) cells are innate-like T cells that share phenotypic characteristics of both NK and conventional T cells (Tconv). Although iNKT cells have been well characterized in mice and humans, functional CD1d and CD1d-restricted iNKT cells are not universally expressed in mammals. Swine express iNKT cells that can be detected using α-galactosylceramide (α-GalCer)-loaded CD1d tetramers. In the present study, we characterized iNKT cells from the blood, spleen, lymph node, lung and liver of commercial mixed-breed pigs, and compared their phenotype to NK cells and Tcon...
Source: Developmental and Comparative Immunology - July 7, 2017 Category: Allergy & Immunology Authors: Yang G, Artiaga BL, Lewis ST, Driver JP Tags: Dev Comp Immunol Source Type: research
A counseling video with pre- and post- testing and checklist for oral immunotherapy consent improves participant knowledge.
CONCLUSION: This is the first study to evaluate the use of a counselling video in conjunction with pre/post-testing to educate families about the key principles of OIT. We suggest that as part of extensive counselling for OIT that an educational video is beneficial in a pediatric outpatient clinic.
PMID: 32650046 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - July 6, 2020 Category: Allergy & Immunology Authors: Mack DP, Foster GA, Bouwers LM, Hanna MA Tags: Ann Allergy Asthma Immunol Source Type: research
A Surgeon-scientist and Entrepreneur Fights Against Cancer
Patrick Soon-Shiong, MD, physician-scientist and entrepreneur, talks about the National MoonShot Initiative, his MoonShot 2020 Program, as well as promising approaches in cancer immunotherapy. This podcast was originally recorded on June 3, 2016
Source: JAMA Author Interviews - September 7, 2016 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
A survey on the perception of allergy specialists about the reimbursed grass pollen tablets for seasonal allergic rhinitis in Italy
Sublingual immunotherapy (SLIT) is a feasible option to classical subcutaneous immunotherapy to treat respiratory allergy and is increasingly prescribed in Europe. However, the lack of reimbursement may limit ...
Source: Clinical and Molecular Allergy - August 15, 2017 Category: Allergy & Immunology Authors: Ilaria Massaro, Oliviero Rossi, Cristoforo Incorvaia and Carlo Lombardi Tags: Research Source Type: research
04:12 PM Abstract No. 226 Glypican-3 optical molecular imaging enables in vivo detection and monitoring of response to adoptive immunotherapy
We have previously described synthesis of a bispecific fusion protein for catheter-directed targeting of glypican-3 (GPC3) expressed on hepatocellular carcinoma (HCC) tumors and CD3 T-cell receptors (GPC3-CD3-bsAb) (1). We hypothesized that in vivo optical fluorescent imaging of GPC3 in mouse models of human HCC would enable effective monitoring of adoptive immunotherapy mediated by GPC3-CD3-bsAb.
Source: Journal of Vascular and Interventional Radiology : JVIR - February 23, 2019 Category: Radiology Authors: P. Habibollahi, J. Hui, M. Mercadante, A. Tsourkas, G. Nadolski, S. Hunt, T. Gade Tags: Scientific Session 23: Nothing Basic About It (Basic Science Oncology) Source Type: research
Treatment with Interleukin-7 Restores Host Defense against Pneumocystis in CD4+ T-Lymphocyte-Depleted Mice Fungal and Parasitic Infections
Pneumocystis pneumonia (PCP) is a major cause of morbidity and mortality in patients with HIV infection. CD4+ T lymphocytes are critical for host defense against this infection, but in the absence of CD4+ T lymphocytes, CD8+ T lymphocytes may provide limited host defense. The cytokine interleukin-7 (IL-7) functions to enhance lymphocyte proliferation, survival, and recruitment of immune cells to sites of infection. However, there is little known about the role of IL-7 in PCP or its potential use as an immunotherapeutic agent. We hypothesized that treatment with recombinant human IL-7 (rhIL-7) would augment host defense aga...
Source: Infection and Immunity - December 28, 2015 Category: Infectious Diseases Authors: Ruan, S., Samuelson, D. R., Assouline, B., Morre, M., Shellito, J. E. Tags: Fungal and Parasitic Infections Source Type: research
Update on adrenocortical carcinoma management and future directions
Purpose of review: To present an update on the management of and future directions in adrenocortical carcinoma (ACC).
Recent findings: ACC is a rare malignancy with high morbidity and mortality. Surgery remains the mainstay treatment for localized disease, but it is often not feasible in more advanced cases. There is an ongoing controversy about the routine use of adjuvant treatments after surgery. Hormonal overproduction can complicate the management and worsen the prognosis of the disease. Systemic therapy with multiple cytotoxic drugs is often combined with the adrenolytic agent mitotane. Genomic analyses of ACC reveal...
Source: Current Opinion in Endocrinology, Diabetes and Obesity - May 5, 2017 Category: Endocrinology Tags: ADRENAL CORTEX AND MEDULLA: Edited by Anand Vaidya Source Type: research
A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy
Hymenoptera venom immunotherapy (VIT) is a clinically effective treatment. However, little is known about its long-term clinical efficacy and biological effects. Several mechanisms have been proposed to account f...
Source: Clinical and Molecular Allergy - January 18, 2018 Category: Allergy & Immunology Authors: Marcello Albanesi, Andrea Nico, Alessandro Sinisi, Lucia Giliberti, Maria Pia Rossi, Margherita Rossini, Georgios Kourtis, Anna Simona Rucco, Filomena Loconte, Loredana Muolo, Marco Zurlo, Danilo Di Bona, Maria Filomena Caiaffa and Luigi Macchia Tags: Research Source Type: research
